Add this topic to your myFT Digest for news straight to your inbox
Less is more for big pharma as buy-backs trump R&D spending
Ian Read’s experience in Latin America is expected to be an asset for Pfizer
New drugs, not big M&A deals, will help the industry rediscover its glory
Seeking growth through the pocketbook, not the test tube
Drug companies are changing their blockbuster model
The lender failed to syndicate €4bn of debt related to Bjorgolfsson’s purchase of a stake in Actavis
Generics is attracting some leading research-led drugmakers
International Edition